Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The emphasis on the Copaxone patents extending to the 3rd quarter of 2015 also was slightly different than most had understood (late 2014). So a possible delay in earnings is another issue from today.

That’s not new information; it has long been known that Teva had a non-Orange-Book process patent (5,800,808) that expires on 9/1/15, 17 years from the issue date.* The list of 7 Orange-Book (which expire on 5/24/14) and 2 non-Orange-Book patents being litigated is shown in #msg-54113660.

*Because the patent was filed prior to the pre-1995 rule change to a duration of 20 years from the filing date (http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5800808.PN.&OS=PN/5800808&RS=PN/5800808 ).